75 related articles for article (PubMed ID: 11051093)
1. A picomolar inhibitor of resistant strains of human immunodeficiency virus protease identified by a combinatorial approach.
Rinnová M; Hradilek M; Barinka C; Weber J; Soucek M; Vondrásek J; Klimkait T; Konvalinka J
Arch Biochem Biophys; 2000 Oct; 382(1):22-30. PubMed ID: 11051093
[TBL] [Abstract][Full Text] [Related]
2. Development of pseudopeptide inhibitors of HIV-1 aspartic protease: analysis and tuning of the subsite specificity.
Tossi A; Antcheva N; Romeo D; Miertus S
Pept Res; 1995; 8(6):328-34. PubMed ID: 8838416
[TBL] [Abstract][Full Text] [Related]
3. Combinatorial design of nonsymmetrical cyclic urea inhibitors of aspartic protease of HIV-1.
Frecer V; Burello E; Miertus S
Bioorg Med Chem; 2005 Sep; 13(18):5492-501. PubMed ID: 16054372
[TBL] [Abstract][Full Text] [Related]
4. Discovery of HIV-1 protease inhibitors with picomolar affinities incorporating N-aryl-oxazolidinone-5-carboxamides as novel P2 ligands.
Ali A; Reddy GS; Cao H; Anjum SG; Nalam MN; Schiffer CA; Rana TM
J Med Chem; 2006 Dec; 49(25):7342-56. PubMed ID: 17149864
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the S3 and S3' subsite specificities of feline immunodeficiency virus (FIV) protease: development of a broad-based protease inhibitor efficacious against FIV, SIV, and HIV in vitro and ex vivo.
Lee T; Laco GS; Torbett BE; Fox HS; Lerner DL; Elder JH; Wong CH
Proc Natl Acad Sci U S A; 1998 Feb; 95(3):939-44. PubMed ID: 9448264
[TBL] [Abstract][Full Text] [Related]
6. Countering cooperative effects in protease inhibitors using constrained beta-strand-mimicking templates in focused combinatorial libraries.
Reid RC; Pattenden LK; Tyndall JD; Martin JL; Walsh T; Fairlie DP
J Med Chem; 2004 Mar; 47(7):1641-51. PubMed ID: 15027855
[TBL] [Abstract][Full Text] [Related]
7. Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir.
Côté HC; Brumme ZL; Harrigan PR
J Virol; 2001 Jan; 75(2):589-94. PubMed ID: 11134271
[TBL] [Abstract][Full Text] [Related]
8. Comparison of inhibitor binding to feline and human immunodeficiency virus proteases: structure-based drug design and the resistance problem.
Dunn BM; Pennington MW; Frase DC; Nash K
Biopolymers; 1999; 51(1):69-77. PubMed ID: 10380354
[TBL] [Abstract][Full Text] [Related]
9. Computational simulations of HIV-1 proteases--multi-drug resistance due to nonactive site mutation L90M.
Ode H; Neya S; Hata M; Sugiura W; Hoshino T
J Am Chem Soc; 2006 Jun; 128(24):7887-95. PubMed ID: 16771502
[TBL] [Abstract][Full Text] [Related]
10. Evolutionary analysis of HIV-1 protease inhibitors: Methods for design of inhibitors that evade resistance.
Stoffler D; Sanner MF; Morris GM; Olson AJ; Goodsell DS
Proteins; 2002 Jul; 48(1):63-74. PubMed ID: 12012338
[TBL] [Abstract][Full Text] [Related]
11. Coevolution and subsite decomposition for the design of resistance-evading HIV-1 protease inhibitors.
Rosin CD; Belew RK; Walker WL; Morris GM; Olson AJ; Goodsell DS
J Mol Biol; 1999 Mar; 287(1):77-92. PubMed ID: 10074408
[TBL] [Abstract][Full Text] [Related]
12. Non-infectious fluorimetric assay for phenotyping of drug-resistant HIV proteinase mutants.
Majerová-Uhlíková T; Dantuma NP; Lindsten K; Masucci MG; Konvalinka J
J Clin Virol; 2006 May; 36(1):50-9. PubMed ID: 16527535
[TBL] [Abstract][Full Text] [Related]
13. Molecular analysis of the HIV-1 resistance development: enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants.
Kozísek M; Bray J; Rezácová P; Sasková K; Brynda J; Pokorná J; Mammano F; Rulísek L; Konvalinka J
J Mol Biol; 2007 Dec; 374(4):1005-16. PubMed ID: 17977555
[TBL] [Abstract][Full Text] [Related]
14. Active-site specificity of digestive aspartic peptidases from the four species of Plasmodium that infect humans using chromogenic combinatorial peptide libraries.
Beyer BB; Johnson JV; Chung AY; Li T; Madabushi A; Agbandje-McKenna M; McKenna R; Dame JB; Dunn BM
Biochemistry; 2005 Feb; 44(6):1768-79. PubMed ID: 15697202
[TBL] [Abstract][Full Text] [Related]
15. Multidrug resistance to HIV-1 protease inhibition requires cooperative coupling between distal mutations.
Ohtaka H; Schön A; Freire E
Biochemistry; 2003 Nov; 42(46):13659-66. PubMed ID: 14622012
[TBL] [Abstract][Full Text] [Related]
16. Comparative studies on inhibitors of HIV protease: a target for drug design.
Jayaraman S; Shah K
In Silico Biol; 2008; 8(5-6):427-47. PubMed ID: 19374129
[TBL] [Abstract][Full Text] [Related]
17. Insight into analysis of interactions of saquinavir with HIV-1 protease in comparison between the wild-type and G48V and G48V/L90M mutants based on QM and QM/MM calculations.
Saen-oon S; Aruksakunwong O; Wittayanarakul K; Sompornpisut P; Hannongbua S
J Mol Graph Model; 2007 Nov; 26(4):720-7. PubMed ID: 17543558
[TBL] [Abstract][Full Text] [Related]
18. Peptidomimetic therapeutic agents targeting the protease enzyme of the human immunodeficiency virus and hepatitis C virus.
Tsantrizos YS
Acc Chem Res; 2008 Oct; 41(10):1252-63. PubMed ID: 18681464
[TBL] [Abstract][Full Text] [Related]
19. Specificity mapping of HIV-1 protease by reduced bond inhibitors.
Majer P; Urban J; Gregorová E; Konvalinka J; Novek P; Stehlíková J; Andreánsky M; Sedlácek J; Strop P
Arch Biochem Biophys; 1993 Jul; 304(1):1-8. PubMed ID: 8323274
[TBL] [Abstract][Full Text] [Related]
20. Beta-lactam compounds as apparently uncompetitive inhibitors of HIV-1 protease.
Sperka T; Pitlik J; Bagossi P; Tözsér J
Bioorg Med Chem Lett; 2005 Jun; 15(12):3086-90. PubMed ID: 15893929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
